Salarius Pharmaceuticals Inc (SLRX): Price and Financial Metrics
SLRX Stock Summary
- The ratio of debt to operating expenses for Salarius Pharmaceuticals Inc is higher than it is for about merely 7.15% of US stocks.
- Equity multiplier, or assets relative to shareholders' equity, comes in at 1.12 for Salarius Pharmaceuticals Inc; that's greater than it is for just 9.56% of US stocks.
- As for revenue growth, note that SLRX's revenue has grown 62.97% over the past 12 months; that beats the revenue growth of 92.03% of US companies in our set.
- Stocks that are quantitatively similar to SLRX, based on their financial statements, market capitalization, and price volatility, are ICCC, ADXS, SOHU, MOSY, and APVO.
- Visit SLRX's SEC page to see the company's official filings. To visit the company's web site, go to www.salariuspharma.com.
SLRX Stock Price Chart Interactive Chart >
SLRX Price/Volume Stats
| Current price | $1.28 | 52-week high | $3.50 |
| Prev. close | $1.27 | 52-week low | $0.56 |
| Day low | $1.25 | Volume | 250,572 |
| Day high | $1.33 | Avg. volume | 2,561,014 |
| 50-day MA | $1.72 | Dividend yield | N/A |
| 200-day MA | $1.17 | Market Cap | 57.26M |
Salarius Pharmaceuticals Inc (SLRX) Company Bio
Salarius Pharmaceuticals Inc is a clinical-stage oncology company. The Company specializes in targeting the epigenetic causes of cancers and developing treatments for patients. Salarius Pharmaceuticals serves patients and customers in the State of Texas.
Latest SLRX News From Around the Web
Below are the latest news stories about Salarius Pharmaceuticals Inc that investors may wish to consider to help them evaluate SLRX as an investment opportunity.
Salarius: Early Stage Nano Cap Targeting CancerPhoto by koto_feja/E+ via Getty ImagesSalarius Pharma (SLRX) was formed through a reverse merger with the erstwhile Flex Pharma. There's not even a trace of Flex in Salarius, investors will be glad to know, because Flex was a loss-making company formed by a Nobel laureate and his friend and a... |
Salarius Pharmaceuticals Reports Business Highlights with Fourth Quarter and Full-Year 2020 Financial ResultsConference Call and Live Audio Webcast Scheduled for Today, Thursday, March 18, 2021, 4:30 p.m. ETHOUSTON, March 18, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, today reported important corporate events and its financial results for the full year and the fourth quarter ended December 31, 2020. “In 2021, we continue to develop our differentiated LSD1 inhibitor, seclidemstat, for the treatment of cancers with high unmet need. During the fourth quarter of 2020 and through early 2021, Salarius achieved two key objectives that are important for the future of the Company: the completion of the dose-escalation stage of t... |
Salarius Pharmaceuticals Inc to Host Earnings CallNEW YORK, NY / ACCESSWIRE / March 18, 2021 / Salarius Pharmaceuticals Inc (NASDAQ:SLRX) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on March 18, 2021 at 4:30 PM Eastern Time.To listen to the event live or access a replay of the call - visit https://www. |
Salarius Announces Closing of $23 Million Underwritten Public Offering of Common Stock Following Full Exercise of Over-Allotment OptionHOUSTON, March 08, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, today announced the closing of its previously announced underwritten public offering of 16,806,722 shares of its common stock, including 2,192,181 shares sold pursuant to the exercise in full of the underwriters’ option to purchase additional shares, at the public offering price of $1.3685 per share. As a result of the underwriters’ over-allotment option exercise, the aggregate gross proceeds to Salarius from the offering, before deducting underwriting discounts and commissions and other offering expenses, were approximately $23 million. “Today’s finan... |
Salarius Announces Pricing of $20 Million Underwritten Public Offering of Common StockHOUSTON, March 04, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, today announced the pricing of an underwritten public offering of 14,614,541 shares of its common stock at a price to the public of $1.3685 per share. The gross proceeds to Salarius from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $20 million. The closing of the offering is expected to take place on or about March 8, 2021, subject to the satisfaction or waiver of customary closing conditions. In addition, Salarius has granted the underwriter a 45-day option to p... |
SLRX Price Returns
| 1-mo | -20.99% |
| 3-mo | 10.34% |
| 6-mo | 50.96% |
| 1-year | 96.05% |
| 3-year | -99.04% |
| 5-year | -99.58% |
| YTD | 40.66% |
| 2020 | -75.93% |
| 2019 | -54.18% |
| 2018 | -90.54% |
| 2017 | -33.90% |
| 2016 | -57.59% |
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
Loading social stream, please wait...